"VSports app下载" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2020 Jul;40(7):1701-1712.
doi: 10.1111/liv.14491. Epub 2020 May 10.

VSports手机版 - Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4

Bjørn S Madsen  1   2 , Maja Thiele  1 , Sönke Detlefsen  3   4 , Mia D Sørensen  1   3   4 , Maria Kjaergaard  1 , Linda S Møller  1 , Ditlev N Rasmussen  1 , Anders Schlosser  5 , Uffe Holmskov  5 , Jonel Trebicka  4   6   7   8 , Grith L Sorensen  5 , Aleksander Krag  1 ; GALAXY consortium
Affiliations

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4

Bjørn S Madsen et al. Liver Int. 2020 Jul.

"V体育ios版" Abstract

Background: Alcoholic liver disease (ALD) is a public health concern that is the cause of half of all cirrhosis-related deaths. Early detection of fibrosis, ideally in the precirrhotic stage, is a key strategy for improving ALD outcomes and for preventing progression to cirrhosis. Previous studies identified the blood-borne marker human microfibrillar-associated protein 4 (MFAP4) as a biomarker for detection of hepatitis C virus (HCV)-related fibrosis. VSports手机版.

Aim: To evaluate the diagnostic accuracy of MFAP4 to detect ALD-induced fibrosis. V体育安卓版.

Method: We performed a prospective, liver biopsy-controlled study involving 266 patients with prior or current alcohol overuse V体育ios版. Patients were split into a training and a validation cohort. .

Results: MFAP4 was present in fibrotic hepatic tissue and serum MFAP4 levels increased with fibrosis grade. The area under the receiver operating characteristic curve (AUROC) for detection of cirrhosis was 0 VSports最新版本. 91 (95% CI 0. 85-0. 96) in the training cohort and 0. 91 (95% CI 0. 79-1. 00) in the validation cohort. For detection of advanced fibrosis, the AUROC was 0. 88 (95% CI 0. 81-0. 94) in the training cohort and 0. 92 (95% CI 0. 83-1. 00) in the validation cohort. The diagnostic accuracy did not differ between MFAP4 and the enhanced liver fibrosis (ELF) test or transient elastography (TE) in an intention-to-diagnose analysis. MFAP4 did not predict hepatic decompensation in a time-to-decompensation analysis in a subgroup of patients with cirrhosis. .

Conclusion: MFAP4 is a novel biomarker that can detect ALD-related fibrosis with high accuracy V体育平台登录. .

Keywords: biomarker; cirrhosis; extracellular matrix protein; liver biopsy; non-invasive testing. VSports注册入口.

PubMed Disclaimer

"VSports" Conflict of interest statement

AS, UH and GLS are inventors of US Patent No. 9,988,442 and EP17199552. 5 owned by University of Southern Denmark. Remaining authors have nothing to declare VSports在线直播.

"V体育2025版" Figures

FIGURE 1
FIGURE 1
MFAP4 concentration in serum according to fibrosis stage. Boxplot of serum MFAP4 in the healthy population group and in the cohort of patients with current or prior alcohol overuse distributed according to the Kleiner fibrosis stage. The box represents the interquartile range. The whiskers indicate the highest and lowest values, and the dots represent outliers. The line across the box indicates the median value
FIGURE 2
FIGURE 2
Immunohistochemical staining of MFAP4 in hepatic tissue. Representative immunohistochemical images of MFAP4 expression in the hepatic tissue in core needle biopsies. Expression of MFAP4 was semiquantitatively scored from 0 to 6. (A‐F) depicts an image of each MFAP4 expression score ranging from 1 to 6. (G) is a case of cirrhosis (Kleiner fibrosis stage 4) with a low MFAP4 expression score of 1. (H) is a case of cirrhosis (Kleiner fibrosis stage 4) with a high MFAP4 expression score of 6
FIGURE 3
FIGURE 3
Distributional plots of serum MFAP4 in the training and validation cohorts. Distributional plots of serum MFAP4 according to advanced fibrosis and cirrhosis in the training and validation cohorts. Rule‐in and rule‐out cut‐offs are marked with a red line. A&B: MFAP4 > 89.3 (U/L) can be used to rule in advanced fibrosis and a MFAP4 < 46.3 (U/L) can be used to rule out advanced fibrosis in the training (A) and the validation cohort (B). C&D: MFAP4 > 104.8 (U/L) can be used to rule in cirrhosis and a MFAP4 < 79.3 (U/L) can be used to rule out cirrhosis in the training (C) and the validation cohort (D)
FIGURE 4
FIGURE 4
Risk prediction and calibration curves according to serum MFAP4. (A and B) Risk prediction curves to evaluate the probability of advanced fibrosis and cirrhosis constructed by logistic regression with serum concentration of MFAP4 in the test cohort. (C and D) Calibration slopes for MFAP4 in the test (yellow) and validation cohort (red). The slopes graph the agreement between predicted probability of advanced fibrosis/cirrhosis on the x‐axis and observed proportion with advanced fibrosis/cirrhosis on the y‐axis. The black dashed line represents perfect calibration, with 100% agreement
FIGURE 5
FIGURE 5
Time to hepatic decompensation in cirrhosis according to MFAP4. A, Kaplan‐Meier plot of hepatic decompensation probability in patients with cirrhosis according to high or low serum concentration of MFAP4. Disease progression did not differ between groups by log‐rank test (P = .670). B, Kaplan‐Meier plot of hepatic decompensation probability in patients with cirrhosis according to high or low expression of MFAP4 in hepatic tissue. Disease progression did not differ between groups by log‐rank test (P = .661)
See this image and copyright information in PMC

References

    1. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999‐2016: observational study. BMJ. 2018;362:k2817. - PMC - PubMed
    1. Hagstrom H, Hemmingsson T, Discacciati A, Andreasson A. Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. J Hepatol. 2018;68(3):505‐510. - PubMed
    1. Williams R, Alexander G, Armstrong I, et al. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2018;391(10125):1097‐1107. - PubMed
    1. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol‐related cirrhosis–early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009;104(5):768‐774. - PubMed
    1. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987‐990. - VSports手机版 - PubMed

Publication types

Substances